SCI Abstract

search
+
Predictive value of ENLIGHT-DP in patients with metastatic lung adenocarcinoma treated with immune checkpoint inhibitors and platinum chemotherapy directly from histopathology slides using inferred transcriptomics
WHAT IS ALREADY KNOWN ON THIS TOPICWHAT THIS STUDY ADDSWe applied ENLIGHT-DP, a novel transcriptomic-based digital patholo...
Utilization of primary tumor samples for cancer neoantigen discovery
IntroductionThe adoptive transfer of tumor-infiltrating T lymphocytes (TIL) recognizing autologous cancer has yielded rema...
Radiomics signature for dynamic monitoring of tumor inflamed microenvironment and immunotherapy response prediction
WHAT IS ALREADY KNOWN ON THIS TOPICWHAT THIS STUDY ADDSThis study introduces a new method, CT-tumor immune microenvironmen...
HDAC and MEK inhibition synergistically suppresses HOXC6 and enhances PD-1 blockade efficacy in BRAFV600E-mutant microsatellite stable colorectal cancer
BackgroundColorectal cancer (CRC) ranks as the third most prevalent malignant tumor worldwide.1 Approximately 10% of CRC c...
Cancer vaccines compensate for the insufficient induction of protective tumor-specific immunity of CD3 bispecific antibody therapy
BackgroundOver the last decade, CD3 bispecific antibody (CD3 bsAb) or “T-cell engager” therapy has become an established t...
Early assessment of IL8 and PD1+ Treg predicts response and guides treatment monitoring in cemiplimab-treated cutaneous squamous cell carcinoma
IntroductionCutaneous squamous cell carcinoma (cSCC) represents a significant burden in dermatological malignancies, being...
FAP-targeted radioligand therapy with 68Ga/177Lu-DOTA-2P(FAPI)2 enhance immunogenicity and synergize with PD-L1 inhibitors for improved antitumor efficacy
WHAT IS ALREADY KNOWN ON THIS TOPICImmune checkpoint blockade immunotherapy alone often yields low response rates, benefit...
PD-1 suppresses human CD38+ circulating Tfr cells and regulates humoral immunity
WHAT IS ALREADY KNOWN ON THIS TOPICProgrammed cell death protein 1 (PD-1) blockade boosts antigen-specific humoral immunit...
MAF1 inhibits hepatocarcinogenesis by fostering an immunostimulatory tumor microenvironment
IntroductionHepatocellular carcinoma (HCC) is the third leading cause of cancer death worldwide and has a dismal survival ...
First-in-human phase I trial of the bispecific CD47 inhibitor and CD40 agonist Fc-fusion protein, SL-172154 in patients with platinum-resistant ovarian cancer
BackgroundIncreased numbers of tumor-infiltrating CD3 T cells and a high M1/M2 ratio of tumor-associated macrophages in ne...
Hyperleukocytosis in a neuroblastoma patient after treatment with natural killer T cells expressing a GD2-specific chimeric antigen receptor and IL-15
InsightsWe report a case of lethal non-clonal hyperleukocytosis in a neuroblastoma patient treated on a phase 1 trial (NCT...
CD93 blockade promotes effector T-cell infiltration and facilitates adoptive cell therapy in solid tumors
WHAT IS ALREADY KNOWN ON THIS TOPICAdaptive cellular therapy (ACT) has been successful in the treatment of hemopoietic mal...
Weal and woe of interleukin-18 in the T cell therapy of cancer
Inducing and sustaining T cell-mediated immune responses against tumor-associated targets is key for successful cancer the...
Safety and efficacy of PD-1 inhibitor (sintilimab) combined with transarterial chemoembolization as the initial treatment in patients with intermediate-stage hepatocellular carcinoma beyond up-to-seven criteria
IntroductionHepatocellular carcinoma (HCC) ranks as the sixth most common cancer globally and the third leading cause of c...
Intratumoral oncolytic virus OH2 injection in patients with locally advanced or metastatic sarcoma: a phase 1/2 trial
WHAT IS ALREADY KNOWN ON THIS TOPICOncolytic viruses have shown promise in enhancing immune responses and eliciting antitu...
Glut3 overexpression improves environmental glucose uptake and antitumor efficacy of CAR-T cells in solid tumors
IntroductionChimeric antigen receptor (CAR) T cells have achieved great success in treating B-cell leukemia and lymphoma.1...
Pancreatic cancer cell-intrinsic transglutaminase-2 promotes T cell suppression through microtubule-dependent secretion of immunosuppressive cytokines
BackgroundPancreatic ductal adenocarcinoma (PDAC) is a highly aggressive malignancy with a 5-year overall survival (OS) ra...
Advances in the understanding and therapeutic manipulation of cancer immune responsiveness: a Society for Immunotherapy of Cancer (SITC) review
Immune checkpoint inhibitors:143 New generation of ICI and stimulatory approaches based on the emerging scientific insight...
Phase I study of BMS-986299, an NLRP3 agonist, as monotherapy and in combination with nivolumab and ipilimumab in patients with advanced solid tumors
IntroductionAlthough the advent of immune checkpoint blockade has changed the treatment landscape across multiple tumor ty...
Pan-tumor analysis to investigate the obesity paradox in immune checkpoint blockade
WHAT IS ALREADY KNOWN ON THIS TOPICWhile obesity predisposes patients to developing cancer, it is also associated with imp...
Targeting IL-33 reprograms the tumor microenvironment and potentiates antitumor response to anti-PD-L1 immunotherapy
IntroductionImmune checkpoint inhibitors (ICIs), especially those targeting programmed cell death protein 1 (PD-1) and the...
Non-invasive multimodal CT deep learning biomarker to predict pathological complete response of non-small cell lung cancer following neoadjuvant immunochemotherapy: a multicenter study
IntroductionLung cancer remains the most lethal malignancy worldwide, characterized by a substantial incidence and mortali...
CHMP2A regulates broad immune cell-mediated antitumor activity in an immunocompetent in vivo head and neck squamous cell carcinoma model
WHAT IS ALREADY KNOWN ON THIS TOPICHOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICYIntroductionNatural killer (NK)...
Favorable impact of PD1/PD-L1 antagonists on bone remodeling: an exploratory prospective clinical study and ex vivo validation
Exploratory longitudinal cohort studyStudy designWe prospectively collected serum samples of patients with advanced solid ...
Combining toll-like receptor agonists with immune checkpoint blockade affects antitumor vaccine efficacy
BackgroundToll-like receptors (TLRs) are evolutionarily conserved receptors, the largest constituents of the pattern recog...
CCR5 and CCL5 in metastatic colorectal cancer
The C-C motif chemokine receptor and ligand type 5 (CCR5 and CCL5, respectively) axis is a well-described pathway in immun...
Preliminary efficacy and safety of YSCH-01 in patients with advanced solid tumors: an investigator-initiated trial
IntroductionCancer is a leading global cause of mortality, accounting for nearly 10.0 million deaths, or approximately one...
Aldehyde dehydrogenase 2-mediated aldehyde metabolism promotes tumor immune evasion by regulating the NOD/VISTA axis
IntroductionImmune evasion plays a key role in tumor progression, which implies that tumors have potential to establish co...
Differential requirements for CD4+ T cells in the efficacy of the anti-PD-1+LAG-3 and anti-PD-1+CTLA-4 combinations in melanoma flank and brain metastasis models
WHAT IS ALREADY KNOWN ON THIS TOPICWHAT THIS STUDY ADDSOur studies suggest that the antitumor activity of the anti-PD-1+LA...
First-in-human study of SBRT and adenosine pathway blockade to potentiate the benefit of immunochemotherapy in early-stage luminal B breast cancer: results of the safety run-in phase of the Neo-CheckRay trial
WHAT IS ALREADY KNOWN ON THIS TOPICHOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE, OR POLICYThe study paves the way for ra...
Load More
format_indent_increase